Weight considerations in psychotropic drug prescribing and switching. - Wikidata - awgldk - TriplyDB

Weight considerations in psychotropic drug prescribing and switching.

Weight considerations in psychotropic drug prescribing and switching.

http://www.wikidata.org/entity/Q38151453

about

Unmet needs of bipolar disorder patients Sex-specific effects of LiCl treatment on preservation of renal function and extended life-span in murine models of SLE: perspective on insights into the potential basis for survivorship in NZB/W female mice Metabolic syndrome among psychiatric outpatients with mood and anxiety disorders.Ranitidine, metformin, and topiramate: managing weight gain in a clozapine-treated patient with schizoaffective disorder.Use of propranolol for hypersexual behavior in an adolescent with autism.Almost all antipsychotics result in weight gain: a meta-analysis.Results from an online survey of patient and caregiver perspectives on unmet needs in the treatment of bipolar disorder.The effects of Jiao-Tai-Wan on sleep, inflammation and insulin resistance in obesity-resistant rats with chronic partial sleep deprivation.Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder.Patients with psychiatric comorbidity can safely undergo bariatric surgery with equivalent success.Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.Metformin for Lithium-induced Weight Gain: A Case Report.Differences in weight change trajectory patterns in a publicly funded adult weight management centre.Bifidobacteria exert strain-specific effects on stress-related behavior and physiology in BALB/c mice.

P2860

Q26738513-AE50B134-B5B0-41AD-8542-18F6E19F26E3 Q26746146-254E0F7F-0CF1-4322-8E8E-FD0C1D1EBEE7 Q33836586-C5D694D5-6DF4-43C6-A9BD-94327680510F Q34331847-12812F50-A032-4D47-BF91-721686D8246B Q34426519-0059B415-18DF-42C9-83A3-EE547E1D26F9 Q34661499-2C967592-AE25-4A84-BD12-099BC7935251 Q35054265-97882AF4-31E5-493F-A59E-1164F218CD92 Q36321002-B658BA7D-4162-4881-AA66-8048873AFE8A Q36446854-1B0B7016-635E-4DBA-B5D8-18FD8D7C1EEC Q37397705-DC4D074D-7CC3-4284-8D8A-332B438FAB65 Q39021125-BD33D645-992E-49CE-B2BC-5B4D4029074C Q39404106-76E7DB15-C905-4AAB-A9FE-A7B71BEB6685 Q41771822-DF3FA36B-90FE-43D0-8F20-53266F217C21 Q42584269-44010B0C-3F14-43DF-8E0F-9DC6A5CD2FC8 Q42684907-128E7E13-EBFF-4522-9975-159201F7D5F1

P2860

Weight considerations in psychotropic drug prescribing and switching.

http://www.wikidata.org/entity/Q38151453

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Weight considerations in psychotropic drug prescribing and switching.

@en

type

label

Weight considerations in psychotropic drug prescribing and switching.

@en

prefLabel

Weight considerations in psychotropic drug prescribing and switching.

@en

P1433

Q38151453-5C42CE3F-6A51-4830-9053-C671389A3FBA

P1476

Q38151453-C4F44FCD-1350-49DA-BB81-EA420FBCD890

P2093

Q38151453-59B935BF-A603-4D96-9615-0A8832A34D89

Q38151453-730F741C-F0CC-4D81-97D9-9632989B226F

P2860

Q38151453-021C9CDC-37B9-4C45-BA43-24C0D18FAC20

Q38151453-0256FDCA-E24D-4E43-A628-BB8D03AACD64

Q38151453-119C3E9B-98A3-4153-9628-36C6237592B6

Q38151453-12460A77-95DB-4DA3-B3D1-098FCF585EF0

Q38151453-136CA819-29AB-4911-A53F-C51076DB3C29

Q38151453-16EA3759-F7F6-4A32-AA51-3F377EDD28E3

Q38151453-257F4CD7-C653-4206-B057-58C647C2DDE6

Q38151453-28B1BFF2-9DF9-420F-A7E5-C523A9FAEE61

Q38151453-30306E44-B8DF-4359-B74C-5063446CEDA1

Q38151453-31CE49A4-B168-48C5-9E08-E3637BD13C6D

P304

Q38151453-B0D547A2-5D92-49D7-8359-ACF911DBC3F3

P31

Q38151453-99E44AD9-B966-4591-81C9-2E3C431C58F9

P356

Q38151453-6A84C43C-DFC4-4B69-8282-B0FA6ED8DDA8

P407

Q38151453-756BFC56-F9E9-4C0C-8339-5AB123315F19

P433

Q38151453-7743A86D-C3A5-4C99-B298-75D126875180

P478

Q38151453-2B8C6F45-6361-4654-B234-660E2414D482

P577

Q38151453-394F59C7-250E-415F-BE79-BFCA7297A8E8

P698

Q38151453-BFCC7CA0-011A-44D5-90FC-37E4E7B27EC1

P356

PGM.2013.09.2706

P1433

Postgraduate Medicine

P1476

Weight considerations in psychotropic drug prescribing and switching.

@en

P2093

Mehrul Hasnain

http://www.w3.org/2001/XMLSchema#string

W Victor R Vieweg

http://www.w3.org/2001/XMLSchema#string

P2860

European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD

ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents

Antidepressants and Body Weight

Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

Association between adult attention deficit/hyperactivity disorder and obesity in the US population

Effects of Nefazodone on Body Weight

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).

P304

117-129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3810/PGM.2013.09.2706

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24113670

http://www.w3.org/2001/XMLSchema#string